ITV News Probe Sparks Calls for Inquiry into Pregnancy Drug

Recent investigations have sparked increased calls for a public inquiry into the pregnancy drug Diethylstilboestrol (DES). Often referred to as the “hidden thalidomide,” this synthetic hormone has affected many women who were prescribed it in the UK from the 1930s to the 1980s.

Background of Diethylstilboestrol (DES)

Doses of DES were administered to approximately 300,000 women by the NHS to prevent miscarriage and treat various other health issues. However, studies later connected DES to rare cancers and infertility among women exposed to the drug.

Formation of DES Justice UK

Following a year-long investigation by ITV News, over 300 victims of DES have united to form the organization DES Justice UK. Their aim is to seek accountability and compensation for the harm they endured.

Health Department Reactions

Health Secretary Wes Streeting has addressed the issue, directing NHS England to collaborate with local cancer alliances. This initiative aims to enhance awareness among general practitioners about the implications of DES and ensure that women who might benefit from additional screening receive adequate care.

Personal Accounts from Victims

• Mary Stuart, 83, took DES in 1966 after enduring repeated miscarriages. Her daughter, Helen Scanlan, now 58, has faced significant health challenges as a result, including cervical cancer and chronic pain.
• Helen expressed her devastation at being unable to start her own family and lives with the ongoing impact of her health issues.
• Mary has publicly shared her guilt over the effects of DES on her daughter, stating she wished she had never taken the drug.

Expert Opinions on Screening

Medical professionals advocate for urgent changes in cancer screening protocols for DES-exposed women. Consultant gynaecologist Dr. Wael Agur reported that standard screening methods may overlook unique risks faced by these women.

Legislative Advocacy and Public Awareness

Alongside the inquiry, stakeholders are advocating for an information campaign aimed at educating healthcare professionals about the dangers of DES. Labour MP Sharon Hodgson emphasized a need for training healthcare providers to ensure they are knowledgeable about historical medical issues.

Call for Compensation and Support

Victims are demanding financial compensation and proper medical support. Clare Fletcher, a partner at Broudie Jackson Canter, remarked that the government must accept responsibility and provide transparency regarding the scandal.

Regulatory Failures and Miscommunication

The Medicines and Healthcare products Regulatory Agency (MHRA) misled the public for decades regarding the withdrawal timeline for DES, attributing much of the confusion to misinformation that dated back to 1973.

Next Steps for Advocacy Groups

DES Justice UK will formally launch its campaign in the Houses of Parliament, where they will meet with Members of Parliament to discuss necessary actions. The group hopes to ensure that victims’ voices are heard and that appropriate measures are implemented for support and compensation.

The plight of DES-exposed women highlights the need for comprehensive public inquiries and the establishment of compensation funds to address the long-term effects of this widely prescribed drug.